Clinical trials: Patient With Schizophrenia Spectrum Disorder
Schizophrenia, Schizoaffective Disorder
Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence
As many as 75 percent of patients with schizophrenia have difficulty taking their oral medication on a regular basis. This may lead to worsening of symptoms.
- Trial name
- NCT00215579
- Testing
- Depot Risperidone Microsphere (Consta)
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Duke University
Schizophrenia
A Study of the Efficacy and Safety of Long-acting Injectable Risperidone and Risperidone Tablets in Patients With Schizophrenia
The purpose of this study is to evaluate the effectiveness and safety of risperidone, formulated as a long-acting injectable drug, compared with risperidone tablets in the treatment of patients with schizophrenia.
- Trial name
- NCT00240708
- Testing
- risperidone
- Volunteers
- 205 people
- Sponsor
- Janssen Pharmaceutical K.K.
Patient Noncompliance
Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic
Psychotropic medications are a cornerstone of treatment for individuals with schizophrenia and schizoaffective disorder, however rates of full or partial non-adherence can exceed 60%.
- Trial name
- CAE-L (NCT01152697)
- Testing
- haloperidol decanoate, haloperidol, Customized Adherence Enhancement
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University Hospitals Cleveland Medical Center
Post Traumatic Stress Disorder, Psychotic Disorders
Effectiveness of Trauma Therapy in Patients With PTSD and Comorbid Psychotic Disorder
Effectiveness of trauma therapy using prolonged exposure for the treatment of post-traumatic stress disorder (PTSD) in patients with comorbid psychotic disorder
- Conditions
- Post Traumatic Stress Disorder, Psychotic Disorders, Psychosis, Schizophrenia
- Trial name
- PEPSY (NCT04911010)
- Testing
- Prolonged Exposure
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- University of Hamburg-Eppendorf
Schizophrenia
Structural and Functional Correlates of Clinical Response to rTMS Treatment in Schizophrenia Patients With Resistant Auditory Hallucinations
The potential of non-invasive Transcranial Magnetic Stimulation (TMS) as a therapeutic tool for improving schizophrenic symptoms, in particular resistant hallucinations, has been increasingly studied over the past decades.
- Trial name
- TMSCCS (NCT02755623)
- Testing
- Repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Centre hospitalier de Ville-Evrard, France
Alcohol Dependence, Schizophrenia
Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism
The aim of this study is to evaluate the safety and efficacy of acamprosate for patients with alcohol dependence and comorbid schizophrenia spectrum disorders.
- Trial name
- NCT00463346
- Testing
- Acamprosate
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Yale University
Schizophrenia
A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia
The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with chronic phase or elderly schizophrenia.
- Trial name
- NCT01625897
- Testing
- MP-214, Risperidone
- Where
- Japan
- Volunteers
- 125 people
- Sponsor
- Tanabe Pharma Corporation
Schizophrenia
Bifeprunox Extension to Extension Study in Patients With Schizophrenia
The purpose of this study is to provide access to bifeprunox for patients, who have completed previous studies with bifeprunox, and require continued treatment with bifeprunox, other treatment not being adequate.
- Trial name
- NCT00861497
- Testing
- Bifeprunox
- Where
- Italy
- Volunteers
- 11 people
- Sponsor
- H. Lundbeck A/S
Body Weight Change, Schizophrenia
Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder
The primary purpose of this study is to compare the affects of aripiprazole and olanzapine on weight change.
- Conditions
- Body Weight Change, Schizophrenia, Schizoaffective Disorder, Psychotic Disorder
- Trial name
- NCT00095524
- Testing
- Aripiprazole
- Where
- 32 sites in United States, Brazil and 1 more
- Volunteers
- 300 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Antipsychotic Effects of Probiotics and Prebiotics on Patients With Schizophrenia
In this study, investigators will evaluate the efficacy and related mechanism of probiotics and prebiotics as an add-on treatment in improving the antipsychotic induced psychotic syndrome, the cognitive impairment…
- Trial name
- NCT04291469
- Testing
- Probiotics（Live combined bifidobacteria, lactobacillus and maltodextrin tables), Prebiotics (Combined inulin and maltodextrin tables), maltodextrin
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Schizophrenia
Effect of Memantine on ERP in Early Schizophrenia and Healthy Subjects
Patients with schizophrenia are deeply affected by the positive symptoms, negative symptoms and cognitive impairment. A generalized cognitive deficit could be frequently observed and traced back to early stage of the disease.
- Trial name
- NCT02233556
- Testing
- Memantine
- Where
- Taiwan
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Schizophrenia
PK Study of Aripiprazole IM Depot for Chinese Patients With Schizophrenia
This study assess pharmacokinetics and safety of multi-administration of Aripiprazole IM Depot formulation at doses of 400mg in patients with schizophrenia.
- Trial name
- NCT03285503
- Testing
- Aripiprazole IM Depot
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Otsuka Beijing Research Institute
Schizophrenia
A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Schizophrenia
This is a Phase 1, open-label study to evaluate the safety and pharmacokinetics (PK) of three doses of risperidone-SABER, administered with a needle and syringe or via the DosePro Needle-Free Delivery System in patients with…
- Trial name
- NCT01592110
- Testing
- risperidone-SABER, ZX003:risperidone-SABER and the DosePro System
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Zogenix, Inc.
Schizophrenia
A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia
The primary objective of the study was to determine the safety of aripiprazole administered long-term in doses ranging from 10 to 30 mg per day as a maintenance therapy in subjects with chronic or first episode of schizophrenia.
- Trial name
- NCT02435836
- Testing
- Aripiprazole
- Volunteers
- 631 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia
This 4-week study will evaluate the safety, tolerability and preliminary evidence of efficacy of evenamide (7.5,and 15 mg and placebo, bid) treatment in outpatients with chronic schizophrenia.
- Trial name
- NCT04461119
- Testing
- Evenamide
- Where
- 14 sites in United States, India
- Volunteers
- 138 people
- Sponsor
- Newron Pharmaceuticals SPA
Schizophrenia
Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia
This will be a multicenter, randomized, double-blind, placebo-controlled study designed to assess the tolerability, safety, and efficacy of OPC-34712 (0.25 to 6.0 mg) for the treatment of adult subjects hospitalized with an acute…
- Trial name
- STEP 203 (NCT00905307)
- Testing
- OPC-34712, Aripiprazole
- Where
- 73 sites in United States, Bulgaria and 10 more
- Volunteers
- 459 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Observational Study to Evaluate Efficacy and Remission Status for Schizophrenia Patients Under Atypical Treatment
The objective of this study is to evaluate under routine clinical setting the efficacy and remission status from treatment of 2nd-generation antipsychotic in patients who is upon acute episode or not achieving remission under…
- Trial name
- QTP NIS (NCT00809731)
- Where
- 17 sites in Taiwan
- Volunteers
- 490 people
- Sponsor
- AstraZeneca
Schizophrenia
NIS to Observe Improvement in Global Assessment of Functioning in Patients With Schizophrenia
The purpose of the study is to monitor the general functional changes among patients with schizophrenia, treated with atypical antipsychotics dosed once daily for a period of 6 months.The primary study objective is to compare…
- Trial name
- NCT00833456
- Where
- 14 sites in Slovenia
- Volunteers
- 106 people
- Sponsor
- AstraZeneca
Severe Mental Illness, Bipolar Disorder
A Mobile App to Support Mood, Daily Routines and Medication Adherence in Adults With Severe Mental Illness
The goal of this clinical trial is to learn whether MoodSync, a mobile application for patients and their family caregivers, improves mood stability, medication adherence, daily functioning and early detection of relapse warning…
- Conditions
- Severe Mental Illness, Bipolar Disorder, Schizophrenia, Schizoaffective Disorder
- Trial name
- MoodSync (NCT07879131)
- Testing
- MoodSync, Standard care
- Where
- Bahrain
- Volunteers
- 60 people
- Sponsor
- Alexandria University
Early Psychosis, Delusions
Intervention to Improve Coping With Negative Emotions in Patients With Psychosis (Feel-Good-Study)
The aim of the present single-centered pre-post study is to assess the feasibility and to investigate the putative efficacy of an emotion-oriented group intervention for patients with psychosis.
- Conditions
- Early Psychosis, Delusions, Emotional Distress, Self Esteem
- Trial name
- NCT04592042
- Testing
- Feel-Good- Group
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- Philipps University Marburg
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.